NCT04915989View on ClinicalTrials.gov

Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
SARS-CoV-2
Interventions
DRUG

GX-19N

DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen

Trial Locations (2)

03722

Severance hospital, Seoul

06273

Gangnam Severance hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT04915989 - Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals | Biotech Hunter | Biotech Hunter